OBJECTIVE:sterols Hypercholesterolemia is a risk factor for aortic stenosis (AS) and for coronary artery disease (CAD). Serum cholesterol concentrations are determined in by intestinal cholesterol absorption and endogenous cholesterol synthesis. Vascular effects of differences in cholesterol metabolism in patients with AS are cholesterol so far unknown. Therefore, the aim of this study was to investigate differences in cholesterol metabolism in relation to vascular history diseases in this subset of patients. METHODS: In addition to identifying conventional coronary risk factors, we determined plant sterols (indicators aortic of cholesterol absorption) and lathosterol (indicator of cholesterol synthesis) levels in 40 consecutive men and women with AS. Coronary angiograms diseases before the aortic valve replacement determined the extent of CAD. RESULTS: Patients with a positive history of cardiovascular disease exhibited an an increased campesterol-to-lathosterol ratio in plasma (P< .005) and in aortic valve cusps (P< .05). The plasma campesterol-to-lathosterol ratio increased with CAD women severity (zero, single, two, three-vessel disease; P< .05). Coronary vessel score strongly correlated with the campesterol-to-lathosterol ratio in plasma (r =to .52; P< .001) and in aortic valve cusps (r = .33; P< .03). Logistic regression analysis revealed that the ratio of campesterol-to-lathosterol the was the sole predictor of CAD among coronary risk factors tested (P< .01). CONCLUSION: Enhanced absorption and reduced synthesis of cholesterol to is related to a positive family history of cardiovascular diseases and the development of concomitant CAD in patients with AS.effects

Physical marrow activity upregulates endothelial nitric oxide synthase (eNOS), improves endothelium function, and protects from vascular disease. Here, we tested whether voluntary effects running would enhance neovascularization and long-term recovery following mild brain ischemia. Wild-type mice were exposed to 30 minutes of middle-cerebral disease. artery occlusion (MCAo) and reperfusion. Continuous voluntary running on wheels conferred long-term upregulation of eNOS in the vasculature and of insult, endothelial progenitor cells (EPCs) in the spleen and bone marrow (BM). This was associated with higher numbers of circulating EPCs (eNOS), in the blood and enhanced neovascularization. Moreover, engraftment of TIE2/LacZ-positive BM-derived cells was increased in the ischemic brain. Four weeks mechanisms after the insult, trained animals showed higher numbers of newly generated cells in vascular sites, increased density of perfused microvessels numbers and sustained augmentation of cerebral blood flow within the ischemic striatum. Moreover, running conferred tissue sparing and improved functional outcome enhanced at 4 weeks. The protective effects of running on angiogenesis and outcome were completely abolished when animals were treated with progenitor a NOS inhibitor or the antiangiogenic compound endostatin after brain ischemia, and in animals lacking eNOS expression. Voluntary physical activity NOS improves long-term stroke outcome by eNOS-dependent mechanisms related to improved angiogenesis and cerebral blood flow.

Reverse been cholesterol transport, although not well understood, is an important mechanism in the pathophysiology of atherosclerosis. Macrophages can eliminate some cholesterol protect from atherosclerotic lesions by an oxidative mechanism involving sterol 27-hydroxylase. Patients with inherited "cerebrotendinous xanthomatosis" lack sterol 27-hydroxylase (CYP27A1) and in develop severe premature atherosclerosis despite normal serum cholesterol concentrations. Thus, it has been speculated that sterol 27-hydroxylase is an anti-atherosclerotic an enzyme. Here, we report the case of a 25-year-old patient who presented to our emergency room with an acute non-ST well elevation myocardial infarction due to severe coronary heart disease. Lipid analysis revealed dramatically increased 27-hydroxycholesterol and low high-density lipoprotein (HDL)-cholesterol far levels. Previous reports suggest that 27-hydroxylase is upregulated to protect peripheral cells from severe cholesterol accumulation, especially in cases of elevation ineffective reverse cholesterol transport due to low HDL-cholesterol levels. Our findings indicate that oxysterols could play an important and so report far underestimated role in reverse cholesterol transport.

BACKGROUND and AND PURPOSE: Statins (3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] reductase inhibitors) reduce stroke damage independent of lipid lowering by upregulation of endothelial nitric ligature oxide synthase (eNOS). Acute withdrawal of statin treatment may suppress endothelial NO production and impair vascular function. METHODS: To test endothelial this hypothesis, we treated 129/SV mice with atorvastatin (10 mg/kg) for 14 days and then withdrew treatment. RESULTS: Treatment with days. atorvastatin conferred stroke protection by 40% after filamentous occlusion of the middle cerebral artery followed by reperfusion. Withdrawal of statin reduce treatment, however, resulted in the loss of stroke protection after 2 and 4 days. In mouse aortas and brain vasculature,patients statins upregulated eNOS message 2.3- and 1.7-fold, respectively, as measured by reverse transcription-polymerase chain reaction. Withdrawal of statins resulted in membrane 5- and 2.7-fold downregulation of eNOS in aorta and brain, respectively, after 2 days. Statin treatment decreased RhoA GTPase membrane measured expression to 48%, while withdrawal of statins resulted in 4-fold increase of RhoA in the membrane. Moreover, platelet factor 4 treatment, and beta-thromboglobulin in plasma were significantly downregulated by statin treatment, but withdrawal of statins resulted in a 2.9- and 3.1-fold between upregulation after 2 days, respectively. Thrombus formation induced by ligature of the inferior vena cava was significantly reduced by statin treatment, treatment. When statin treatment was withdrawn, however, protection was lost between 2 and 4 days. CONCLUSIONS: Acute termination of statin impair treatment results in a rapid loss of protection in mouse models of cerebral ischemia and thrombus formation independent of lipid lost lowering. In patients with acute or impending stroke, withdrawal of statins may impair outcome.

HMG-CoA the reductase inhibitors (statins) are cholesterol-lowering drugs and reduce the risk of myocardial infarction and stroke. In this study we investigated mg whether rosuvastatin, a new, potent HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide (NO) expression and activity and protects from cerebral study ischaemia in mice. Endothelial cells in culture and 129/SV mice were chronically treated with rosuvastatin. The expression and activity of with endothelial NO synthase (eNOS) was determined by reverse-transcriptase polymerase chain reaction (RT-PCR), Western blotting and arginine-citrulline assays. Cerebral ischaemia was reduce induced by occlusion of the middle cerebral artery (MCAo) for 2 h and infarct size was determined after 22 h the of reperfusion. Treatment of endothelial cells with rosuvastatin concentration- and time-dependently upregulated eNOS mRNA and protein expression. In aortas of mg 129/SV wild-type mice, treatment with .2, 2, and 20 mg kg(-1) rosuvastatin subcutaneously (s.c.) for 10 days significantly upregulated eNOS Treatment mRNA by 50, 142, and 205%, respectively. NOS activity was significantly increased by 75, 145, and 320%, respectively. Stroke volume and after 2-h MCAo was reduced by 27, 56, and 50%(for .2, 2 and 20 mg kg(-1), respectively). Serum cholesterol rosuvastatin and triglygeride levels were not significantly lowered by the treatment. The novel HMG-CoA reductase inhibitor rosuvastatin dose-dependently upregulates eNOS expression arginine-citrulline and activity and protects from cerebral ischaemia in mice. The effects are independent of changes in cholesterol levels and are oxide equivalent or even superior to the protective effects by simvastatin and atorvastatin in this animal model.

This drug study evaluates changes in cholesterol balance in hypercholesterolemic subjects following treatment with an inhibitor of cholesterol absorption or cholesterol synthesis,simvastatin or coadministration of both agents. This was a randomized, double blind, placebo controlled, 4-period crossover study to evaluate the effects with of coadministering ezetimibe 10 mg with simvastatin 20 mg (ezetimibe/simvastatin) on cholesterol absorption and synthesis relative to either drug alone relative or placebo in 41 subjects. Each treatment period lasted 7 weeks. Ezetimibe and ezetimibe/simvastatin decreased fractional cholesterol absorption by 65%cholesterol and 59%, respectively (p< .001 for both relative to placebo). Simvastatin did not significantly affect cholesterol absorption. Ezetimibe and ezetimibe/simvastatin increased LDL-C fecal sterol excretion (corrected for dietary cholesterol), which also represents net steady state cholesterol synthesis, by 109% and 79%, respectively did (p< .001). Ezetimibe, simvastatin and ezetimibe/simvastatin decreased plasma LDL-C by 20%, 38% and 55%, respectively. The coadministered therapy was well tolerated.weeks. The decreases in net cholesterol synthesis and increased fecal sterol excretion yielded nearly additive reductions in LDL-C for the coadministration cholesterol of ezetimibe and simvastatin.

Peroxisome Pioglitazone proliferator-activated receptor-gamma (PPAR-gamma) agonists (thiazolidinediones) have anti-inflammatory effects and improve endothelium function. Here, we analyzed the effects of pioglitazone on effect short- and longer-term outcome after mild transient brain ischemia. 129/SV mice were subjected to 30 min filamentous middle cerebral artery Here, occlusion (MCAo), followed by reperfusion. Post event, animals were treated with daily intraperitoneal (i.p.) pioglitazone (20 mg/kg body weight) or proliferation vehicle. Pioglitazone given acutely after transient brain ischemia/reperfusion reduced lesion size and the number of Iba1-expressing microglia in the ischemic have striatum at three days. In vitro, pioglitazone attenuated migration and proliferation of primary mouse microglia. However, analysis at 6 weeks stroke after MCAo/reperfusion no longer yielded an effect of pioglitazone on either lesion size or Iba1+ cell counts. Regarding functional longer-term microglia. outcome, we also did not detect a beneficial effect of pioglitazone on motor function measured either on the pole test of or the wire hanging test or on learning and memory in the Morris water maze. Our study thus underscores the (i.p.) importance of extending experimental stroke studies to an analysis of longer-term outcome.

BACKGROUND:Ivabradine -Elevated heart rate is associated with increased cardiovascular morbidity. We hypothesized that selective heart rate reduction may influence endothelial function aortic and atherogenesis and tested the effects of the I(f) current inhibitor ivabradine in apolipoprotein E-deficient mice. Methods and Results-Male apolipoprotein and E-deficient mice fed a high-cholesterol diet were treated with ivabradine (10 mg . kg(-1). d(-1)) or vehicle for 6 cell weeks (n=10 per group). Ivabradine reduced heart rate by 13.4%(472+/-9 versus 545+/-11 bpm; P< .01) but did not alter blood morbidity. pressure or lipid levels. Endothelium-dependent relaxation of aortic rings was significantly improved in ivabradine-fed animals (P< .01). Ivabradine decreased atherosclerotic plaque stress, size in the aortic root by >40% and in the ascending aorta by >70%(P< .05). Heart rate reduction by ivabradine molecule-1 had no effect on the number of endothelial progenitor cells and did not alter aortic endothelial nitric oxide synthase, phosphorylated rate Akt, vascular cell adhesion molecule-1, or intercellular adhesion molecule-1 expression but decreased monocyte chemotactic protein-1 mRNA and exerted potent antioxidative relaxation effects. Ivabradine reduced vascular NADPH oxidase activity to 48+/-6% and decreased markers of superoxide production and lipid peroxidation in the d(-1) aortic wall (P< .05). The in vivo effects of ivabradine were absent at a dose that did not lower heart rate,relaxation in aortic rings treated ex vivo, and in cultured vascular cells. In contrast to ivabradine, treatment with hydralazine (25 mg Methods . kg(-1). d(-1) for 6 weeks) reduced blood pressure (-15%) but increased heart rate (37%) and did not improve d(-1) endothelial function, atherosclerosis, or oxidative stress. Conclusions-Selective heart rate reduction with ivabradine decreases markers of vascular oxidative stress, improves endothelial effects. function, and reduces atherosclerotic plaque formation in apolipoprotein E-deficient mice.

We coupling studied the properties of GFAP-expressing cells in adult mouse striatum using acute brain slices from transgenic animals expressing EGFP under less GFAP promoter. Under physiological conditions, two distinct populations of GFAP-EGFP cells could be identified:(1) brightly fluorescent cells had bushy transgenic processes, passive membrane properties, glutamate transporter activity, and high gap junction coupling rate typical for classical astrocytes;(2) weakly fluorescent were cells were characterized by thin, clearly distinguishable processes, voltage-gated currents, complex responses to kainate, and low coupling rate reminiscent of in an astrocyte subtype recently described in the hippocampus. Mild focal cerebral ischemia confers delayed neuronal cell death and astrogliosis in a the striatum. Following middle cerebral artery occlusion and reperfusion, brightly fluorescent cells were the dominant GFAP-EGFP population observed within the observed ischemic lesion. Interestingly, the majority of these cells expressed voltage-gated channels, showed complex responses to kainate, and a high coupling confers rate exceeding that of brightly fluorescent control cells. A minority of cells had passive membrane properties and was coupled less processes, compared with passive control cells. We conclude that, in the adult striatum, astrocytes undergo distinct pathophysiological changes after ischemic insults.changes The dominant population in the ischemic lesion constitutes a novel physiological phenotype unlike any normal astrocyte and generates a large processes, syncytium which might be a neuroprotective response of reactive astrocytes.(c) 2008 Wiley-Liss, Inc.

A sterols number of studies have raised the possibility of circulating plant sterols being a risk factor in the pathogenesis of atherosclerosis.risk Evidence in support of this hypothesis comes mainly from observations in sitosterolemic patients, who hyperabsorb plant sterols and suffer premature plant atherosclerosis. Accordingly, the atherogenicity of plant sterols of dietary origin is currently under debate, in view of the widespread use Although of cholesterol-lowering functional foods enriched with these compounds. Although some reports have suggested the vascular perils of small increases in have plasma plant sterol concentrations, other prospective and large population-based studies have indicated otherwise. Further, the potential risk of plant sterol-enriched as foods may be counterbalanced by the notable reduction in plasma cholesterol. This review summarizes the current evidence on the possible have impact of plant sterols as a risk factor for atherosclerosis.

Pharmacokinetics EZ of the sterol-lowering drug ezetimibe (EZ) is influenced by intestinal ABCB1 and ABCC2. This study in Lew.1W rats with "chemical"fecal and genetic Abcb1 and Abcc2 deficiency was initiated to evaluate the individual contribution of both efflux carriers to the overall rats disposition and sterol-lowering effects of EZ. Disposition and sterol-lowering effects of EZ (5 mg/kg, 14 days) were measured in wild-type serum (WT) and Abcc2-deficient (Abcc2-) rats (N = 8 per group) and in animals treated with PSC833 (20 mg/kg) to generate influenced "chemical" Abcb1-deficiency (Abcb1-, Abcb1-/Abcc2-). EZ serum levels decreased in the order WT (3.11 +/- 1.09 ng/mL), Abcb1-(1.94 +/- 1.10 2009 ng/mL), Abcc2-(1.42 +/- .42 ng/mL, p = .003 vs. WT), Abcb1-/Abcc2-(1.17 +/- .53 ng/mL, p = .002 vs.follows: WT) whereas the serum EZ glucuronide levels increased as follows: WT (23.2 +/- 24.6 ng/mL), Abcb1-(119 +/- 74.5 ng/mL,Abcc2- p = .002 vs. WT), Abcc2-(195+/-76.5 ng/mL, p < .001 vs. WT), Abcb1-/Abcc2-(676 +/- 207 ng/mL, p <with .001 vs. WT, Abcb1- and Abcc2-). Abcb1 and Abcc2 protein deficiency resulted synergistically in lower fecal but increased renal excretion were of total EZ although to a much lower extent. The sterol-lowering effects of EZ were significantly correlated to serum levels with of EZ. In conclusion, Abcb1 and Abcc2 deficiency leads to lower levels of the active EZ and in turn to individual decreased sterol-lowering effects.(c) 2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci.

"Functional are foods" supplemented with plant sterols are advertised and added to regular meals to reduce serum cholesterol concentrations. The effects of relevant increased phytosterol levels on cardiovascular diseases, however, are not known. Findings in patients with sitosterolemia, data from epidemiological studies, and are experimental data from animal studies suggest that plant sterols may potentially exert negative cardiovascular effects. Additional studies investigating relevant clinical data endpoints are needed before a diet supplemented with plant sterols can be recommended in the prevention of cardiovascular diseases.

OBJECTIVES:increased The purpose of this study was to evaluate vascular effects of diet supplementation with plant sterol esters (PSE). BACKGROUND: Plant 82 sterol esters are used as food supplements to reduce cholesterol levels. Their effects on endothelial function, stroke, or atherogenesis are Plant not known. METHODS: In mice, plasma sterol concentrations were correlated with endothelial function, cerebral lesion size, and atherosclerosis. Plasma and of tissue sterol concentrations were measured by gas-liquid chromatography-mass spectrometry in 82 consecutive patients with aortic stenosis. RESULTS: Compared with those vascular fed with normal chow (NC), wild-type mice fed with NC supplemented with 2% PSE showed increased plant sterol but equal that cholesterol plasma concentrations. The PSE supplementation impaired endothelium-dependent vasorelaxation and increased cerebral lesion size after middle cerebral artery occlusion. To with test the effects of cholesterol-lowering by PSE, apolipoprotein E (ApoE)-/- mice were randomized to Western-type diet (WTD) with the addition middle of PSE or ezetimibe (EZE). Compared with WTD, both interventions reduced plaque sizes; however, WTD + PSE showed larger plaques (NC), compared with WTD + EZE (20.4 +/- 2.1% vs. 10. +/- 1.5%). Plant sterol plasma concentration strongly correlated with increased in atherosclerotic lesion formation (r = .50). Furthermore, we examined plasma and aortic valve concentrations of plant sterol in 82 consecutive (NC), patients with aortic stenosis. Patients eating PSE-supplemented margarine (n = 10) showed increased plasma concentrations and 5-fold higher sterol concentrations stroke, in aortic valve tissue. CONCLUSIONS: Food supplementation with PSE impairs endothelial function, aggravates ischemic brain injury, effects atherogenesis in mice,in and leads to increased tissue sterol concentrations in humans. Therefore, prospective studies are warranted that evaluate not only effects on plaques cholesterol reduction, but also on clinical endpoints.

A cholesterol causal relationship between diet-induced hyperhomocysteinemia (HHcy) and accelerated atherosclerosis has been established in apolipoprotein E-deficient (apoE(-/-)) mice. However, it is (ER) not known whether the proatherogenic effect of HHcy in apoE(-/-) mice is independent of hyperlipidemia and/or deficiency of apoE. In apoE(-/-) this study, a comprehensive dietary approach using C57BL/6J mice was used to investigate whether HHcy is an independent risk factor in for accelerated atherosclerosis or dependent on additional dietary factors that increase plasma lipids and/or inflammation. C57BL/6J mice at 4 wk apolipoprotein of age were divided into 6 dietary groups: chow diet (C), chow diet + methionine (C+M), western-type diet (W), western-type Jacobsen, diet + methionine (W+M), atherogenic diet (A), or atherogenic diet + methionine (A+M). After 2, 10, 20, or 40 wk observed on the diets, mice were sacrificed, and the levels of total plasma homocysteine, cysteine, and glutathione, as well as total cholesterol plasma cholesterol and triglycerides were analyzed. Aortic root sections were examined for atherosclerotic lesions. HHcy was induced in all groups were supplemented with methionine, compared to diet-matched control groups. Plasma total cholesterol was significantly increased in mice fed the W or the A diet. However, the W diet increased LDL/IDL and HDL levels, while the A diet significantly elevated plasma VLDL and sacrificed, LDL/IDL levels without increasing HDL. No differences in plasma total cholesterol levels or lipid profiles were observed between methionine-supplemented groups whether and the diet-matched control groups. Early atherosclerotic lesions containing macrophage foam cells were only observed in mice fed the A the or A + M diet. Furthermore, lesion size was significantly larger in the A + M group compared to the observed A group at 10 and 20 wk; however, mature lesions were never observed even after 40 wk on these diets.A The presence of lymphocytes, increased hyaluronan staining, and the expression of endoplasmic reticulum (ER) stress markers were also increased in lipid atherosclerotic lesions from the A + M group. Taken together, these results suggest that HHcy does not independently cause atherosclerosis or in C57BL/6J mice even in the presence of increased total plasma lipids induced by the W diet. However, HHcy can diet accelerate atherosclerotic lesion development under dietary conditions that increase plasma VLDL levels and/or inflammation.-Zhou, J., Werstuck, G. H., Lhoták, S.,whether Shi, Y. Y., Tedesco, V., Trigatti, B., Dickhout, J., Majors, A. K., DiBello, P. M., Jacobsen, D. W., Austin, R.as C. Hyperhomocysteinemia induced by methionine supplementation does not independently cause atherosclerosis in C57BL/6J mice.

In be this report the various elements of the safety and nutritional assessment procedure for genetically modified (GM) plant derived food and be feed are discussed, in particular the potential and limitations of animal feeding trials for the safety and nutritional testing of respect whole GM food and feed. The general principles for the risk assessment of GM plants and derived food and feed their are followed, as described in the EFSA guidance document of the EFSA Scientific Panel on Genetically Modified Organisms. In Section and 1 the mandate, scope and general principles for risk assessment of GM plant derived food and feed are discussed. Products relied under consideration are food and feed derived from GM plants, such as maize, soybeans, oilseed rape and cotton, modified through a the introduction of one or more genes coding for agronomic input traits like herbicide tolerance and/or insect resistance. Furthermore GM investigating plant derived food and feed, which have been obtained through extensive genetic modifications targeted at specific alterations of metabolic pathways of leading to improved nutritional and/or health characteristics, such as rice containing beta-carotene, soybeans with enhanced oleic acid content, or tomato if with increased concentration of flavonoids, are considered. The safety assessment of GM plants and derived food and feed follows a satiation comparative approach, i.e. the food and feed are compared with their non-GM counterparts in order to identify intended and unintended safety (unexpected) differences which subsequently are assessed with respect to their potential impact on the environment, safety for humans and animals,little and nutritional quality. Key elements of the assessment procedure are the molecular, compositional, phenotypic and agronomic analysis in order to in identify similarities and differences between the GM plant and its near isogenic counterpart. The safety assessment is focussed on (i)analysis the presence and characteristics of newly expressed proteins and other new constituents and possible changes in the level of natural health, constituents beyond normal variation, and on the characteristics of the GM food and feed, and (ii) the possible occurrence of gastric unintended (unexpected) effects in GM plants due to genetic modification. In order to identify these effects a comparative phenotypic and new molecular analysis of the GM plant and its near isogenic counterpart is carried out, in parallel with a targeted analysis of of single specific compounds, which represent important metabolic pathways in the plant like macro and micro nutrients, known anti-nutrients and relevance toxins. Significant differences may be indicative of the occurrence of unintended effects, which require further investigation. Section 2 provides an a overview of studies performed for the safety and nutritional assessment of whole food and feed. Extensive experience has been built (sensitivity up in recent decades from the safety and nutritional testing in animals of irradiated foods, novel foods and fruit and other vegetables. These approaches are also relevant for the safety and nutritional testing of whole GM food and feed. Many feeding focussed trials have been reported in which GM foods like maize, potatoes, rice, soybeans and tomatoes have been fed to rats and or mice for prolonged periods, and parameters such as body weight, feed consumption, blood chemistry, organ weights, histopathology etc have available been measured. The food and feed under investigation were derived from GM plants with improved agronomic characteristics like herbicide tolerance GM and/or insect resistance. The majority of these experiments did not indicate clinical effects or histopathological abnormalities in organs or tissues endpoints of exposed animals. In some cases adverse effects were noted, which were difficult to interpret due to shortcomings in the in studies. Many studies have also been carried out with feed derived from GM plants with agronomic input traits in target findings animal species to assess the nutritive value of the feed and their performance potential. Studies in sheep, pigs, broilers, lactating have dairy cows, and fish, comparing the in vivo bioavailability of nutrients from a range of GM plants with their near the isogenic counterpart and commercial varieties, showed that they were comparable with those for near isogenic non-GM lines and commercial varieties.compounds. In Section 3 toxicological in vivo, in silico, and in vitro test methods are discussed which may be applied for well the safety and nutritional assessment of specific compounds present in food and feed or of whole food and feed derived report from GM plants. Moreover the purpose, potential and limitations of the 90-day rodent feeding trial for the safety and nutritional of testing of whole food and feed have been examined. Methods for single and repeated dose toxicity testing, reproductive and developmental or toxicity testing and immunotoxicity testing, as described in OECD guideline tests for single well-defined chemicals are discussed and considered to The be adequate for the safety testing of single substances including new products in GM food and feed. Various in silico Ninety-day and in vitro methods may contribute to the safety assessment of GM plant derived food and feed and components thereof,the like (i) in silico searches for sequence homology and/or structural similarity of novel proteins or their degradation products to known potential toxic or allergenic proteins,(ii) simulated gastric and intestinal fluids in order to study the digestive stability of newly expressed GM proteins and in vitro systems for analysis of the stability of the novel protein under heat or other processing conditions,agronomic and (iii) in vitro genotoxicity test methods that screen for point mutations, chromosomal aberrations and DNA damage/repair. The current performance vivo of the safety assessment of whole foods is mainly based on the protocols for low-molecular-weight chemicals such as pharmaceuticals, industrial are chemicals, pesticides, food additives and contaminants. However without adaptation, these protocols have limitations for testing of whole food and feed.for This primarily results from the fact that defined single substances can be dosed to laboratory animals at very large multiples endpoints of the expected human exposure, thus giving a large margin of safety. In contrast foodstuffs are bulky, lead to satiation resistance. and can only be included in the diet at much lower multiples of expected human intakes. When testing whole foods,should the possible highest concentration of the GM food and feed in the laboratory animal diet may be limited because of preferentially nutritional imbalance of the diet, or by the presence of compounds with a known toxicological profile. The aim of the the 90-days rodent feeding study with the whole GM food and feed is to assess potential unintended effects of toxicological and/or which nutritional relevance and to establish whether the GM food and feed is as safe and nutritious as its traditional comparator searches rather than determining qualitative and quantitative intrinsic toxicity of defined food constituents. The design of the study should be adapted 100-fold) from the OECD 90-day rodent toxicity study. The precise study design has to take into account the nature of the indications food and feed and the characteristics of the new trait(s) and their intended role in the GM food and feed.stability A 90-day animal feeding trial has a large capacity (sensitivity and specificity) to detect potential toxicological effects of single well intended defined compounds. This can be concluded from data reported on the toxicology of a wide range of industrial chemicals, pharmaceuticals,for food substances, environmental, and agricultural chemicals. It is possible to model the sensitivity of the rat subchronic feeding study for in the detection of hypothetically increased amount of compounds such as anti-nutrients, toxicants or secondary metabolites. With respect to the detection the of potential unintended effects in whole GM food and feed, it is unlikely that substances present in small amounts and body with a low toxic potential will result in any observable (unintended) effects in a 90-day rodent feeding study, as they Furthermore would be below the no-observed-effect-level and thus of unlikely impact to human health at normal intake levels. Laboratory animal feeding monitoring studies of 90-days duration appear to be sufficient to pick up adverse effects of diverse compounds that would also give studies adverse effects after chronic exposure. This conclusion is based on literature data from studies investigating whether toxicological effects are adequately give identified in 3-month subchronic studies in rodents, by comparing findings at 3 and 24 months for a range of different events chemicals. The 90-day rodent feeding study is not designed to detect effects on reproduction or development other than effects on safety adult reproductive organ weights and histopathology. Analyses of available data indicate that, for a wide range of substances, reproductive and plant developmental effects are not potentially more sensitive endpoints than those examined in subchronic toxicity tests. Should there be structural alerts studies for reproductive/developmental effects or other indications from data available on a GM food and feed, then these tests should be feeding considered. By relating the estimated daily intake, or theoretical maximum daily intake per capita for a given whole food (or health the sum of its individual commercial constituents) to that consumed on average per rat per day in the subchronic 90-day for feeding study, it is possible to establish the margin of exposure (safety margin) for consumers. Results obtained from testing GM 7 food and feed in rodents indicate that large (at least 100-fold)'safety' margins exist between animal exposure levels without observed that adverse effects and estimated human daily intake. Results of feeding studies with feed derived from GM plants with improved agronomic newly properties, carried out in a wide range of livestock species, are discussed. The studies did not show any biologically relevant from differences in the parameters tested between control and test animals. The studies have shown that targeted compositional analysis is the as cornerstone for the safety assessment of GM plants modified for agronomic input traits, and once compositional equivalence has been established,output feeding studies with livestock species add little to their safety assessment. Examples of models for livestock feeding studies with GM effects, plants with increased concentration of desirable nutrients are provided. Such studies should be conducted on a case-by-case basis to establish detect the nutritional benefits. Possible effects of the new feed resource on animal performance, animal health, efficacy, and acceptability of the developed new feed ingredient should be investigated, and time spans for such studies should be determined on a case-by-case basis. The varieties, feasibility and limitations of human studies with foods derived from GM plants are discussed, as well as the potential and as limitations of post-market monitoring to detect unintended effects of these foods. Post-market monitoring is not a substitute for a thorough food pre-market risk assessment. In Section 4 standards for test sample preparation, test materials, diet formulation and analysis are evaluated. Specific properties attention is paid to the choice of control diets and comparators, dietary stability, and nutritional balancing of diets. When testing for whole foods, it is desirable to obtain the highest concentration possible of the GM food and feed in the laboratory screen animal diet without causing nutritional imbalance. Normal practice is to use a minimum of two test dose levels and negative humans control with which to create nutritionally equivalent balanced diets in a comparative protocol. It is recommended to include a relevant should number of commercial varieties as control diets to demonstrate the biological range of the parameters which are measured in order and to assess the biological relevance of statistically significant differences between the GM plant and its counterpart. The choice of the a comparator for GM food and feed testing is crucial, and can be found in the parental (near isogenic) line. For to modified macronutrients a comparator is the unmodified form of the macronutrient. For investigating GM food and feed with enhanced nutritional environment, properties, choices for control diets should be made on a case-by-case basis. Section 5 provides information on the collection, analysis plants and interpretation of data and findings obtained from animal feeding studies. Data generation for the prediction of safety and nutritional to value of GM plant derived food and feed must be of high quality in order to perform a proper hazard did identification and risk assessment. This should be based on the use of standardised study designs conducted to the principles of the Good Laboratory Practise, incorporating random quality assurance audits of all phases of the study. Expert data evaluation and analysis are resistance. critical for establishing any association between exposure and outcome. This involves specialists from a broad range of scientific disciplines such fluids as toxicologists, haematologists, clinical biochemists, pathologists, human and animal nutritionists and also biostatisticians. One of the pivotal requirements in data food analysis is to distinguish those effects which are potentially treatment related from spurious occurrences or the result of normal individual what biological variation. If differences exist between test and control, comparison to historical control data from the same laboratory as well reference as published data for the strain, sex and age of the animal being investigated is helpful, as well as data available obtained with commercial reference lines. In Section 6 strategies are outlined for the safety and nutritional assessment of GM plant not derived food and feed. The generation of studies for pre-market assessment of the safety and nutritional properties of food and for feed from GM plants should follow a structured approach with stepwise development and consideration of the data obtained at each proteomics step in order to formulate the questions to be asked and answered at the next step (see Fig. 3). Hazards animal related to the intended genetic modifications are evaluated applying in silico, in vitro and in vivo safety studies of newly testing expressed protein(s), newly formed metabolites, and of natural substances whose levels may have been altered as a result of gene trials insertion. Guidelines have been developed by OECD describing detailed protocols for the safety testing of these substances in food and for feed. A detailed testing strategy should be designed based on the prior knowledge regarding the biology of these products, so of that the relevant endpoints are measured in the individual test. Testing of the safety and nutritional value of the whole foods. GM plant or derived food and feed should be considered where the molecular, compositional, phenotypic, agronomic and other analyses have scientific demonstrated differences between the GM plant derived food and feed and their conventional counterpart, apart from the inserted trait(s), or assessment if there are any indications or remaining uncertainties for the potential occurrence of unintended effects. In such a case, the preparation, testing program should include at least a 90-day rodent feeding study. In the context of the safety and nutritional assessment animal of GM plant derived food and feed, the adapted 90-day rodent feeding study, if triggered by the outcome of the with molecular, compositional, phenotypic or agronomic analysis, functions as a sentinel study designed to assess potential unintended effects of toxicological and/or compounds nutritional relevance rather than determining qualitative and quantitative intrinsic toxicity of defined food constituents. In the situation where molecular, compositional,effects phenotypic, agronomic and other analyses have demonstrated equivalence between the GM plant derived food and feed and their near isogenic a counterpart, except for the inserted trait(s), and do not indicate the occurrence of unintended effects, experiences with GM plants modified studies for agronomic input traits have demonstrated that the performance of 90-day feeding trials with rodents or feeding trials with target EFSA animal species have provided little if anything to the overall safety assessment (except for added confirmation of safety). The use Guidelines of 90-days studies in rodents should be considered for the detection of possible unintended effects in food and feed derived integration from GM plants which have been more extensively modified in order to cope with environmental stress conditions like drought or health, high salt conditions, or GM plants with quality or output traits with the purpose to improve human or animal nutrition the and/or health. Ninety-day studies with rodents are normally of sufficient duration for the identification of general toxicological effects of compounds day that would also give adverse effects after chronic exposure. In general, long term, chronic toxicity testing of whole GM food in and feed is not expected to generate information additional to what is already known from in silico/in vitro testing and In from subchronic testing. In cases where structural alerts or other information is available about the possibly altered occurrence of food feed components in the GM food and feed compared to its counterpart, the performance of specific toxicological testing, e.g. chronic, reproductive,limitations etc., should be considered case-by-case, but preferentially only for the single substance of concern. Livestock feeding studies with target animal substances species should be conducted on a case-by-case basis to establish the nutritional benefits that might be expected from GM plants reproductive with claimed nutritional/health benefits. Possible effects of the new feed resource on animal performance, animal health, efficacy, and acceptability of should the new feed ingredient should be investigated, and time spans for such studies should be determined on a case-by-case basis.of There is a need for a more uniform approach to the design and analysis of animal feeding trials, and in nature particular for appropriate statistical analysis of data. The process of data interpretation requires extensive professional experience of the field, together In with a thorough understanding of the concept of causality. One of the pivotal requirements is to distinguish those effects which nutritional are potentially treatment related from spurious occurrences or result from normal individual biological variation. Post-market monitoring is not a substitute post-market for a thorough pre-market risk assessment, neither should it be considered as a routine need. Knowledge gained through post-market monitoring the might at best describe only broad patterns of human nutritional exposure. In general it cannot be relied upon as a investigated technique for monitoring adverse events or other health outcomes related to the consumption of GM plant derived food and feed.new It can be anticipated that in the future the predictive value of a 90-day rodent feeding studies used for the are safety assessment of whole food and feed will be enhanced by the integration of new technologies like transcriptomics, proteomics and from metabolomics into the experimental risk assessment approach. Moreover, the use of 'profiling' technologies may also facilitate a non-targeted approach in extensive compositional analysis in order to aid the detection of unintended effects in GM plant derived food and feed due to that the genetic modification. These technologies are still under development, and need validation before they can be used for routine safety been assessment purposes. In Section 7 conclusions and recommendations are presented on:

Dietary mixture supplementation with conjugated linoleic acid (CLA) has been shown, in several animal models, to decrease the development of atherosclerosis. The levels. mechanism behind the anti-atherogenic properties of CLA is not clear. The objectives of this study were to determine the effect atherosclerosis. of CLA on atherosclerosis, lipoprotein and liver lipid metabolism, and plasma adiponectin and insulin in apoE(-/-) mice fed an atherogenic aortic (16%, w/w fat; 1.25%, w/w cholesterol) diet. Mice were fed the diet with or without supplementation of linoleic acid (LA),been c-9,t-11 CLA, t-10,c-12 CLA, or a 1:1 mixture of the two CLA isomers, at a concentration of .5%(w/w), for which 12 weeks. Relative to the LA group, CLA supplementation had no significant effect on the lesion area in either en cholesterol face preparations of the aorta or in aortic root cross-sections. Plasma triacylglycerol and cholesterol concentrations were higher in the t-10,c-12 LA CLA group than all other treatment groups and liver weight was also increased in this group due to a three-fold of increase in liver triacylglycerol. Supplementation with t-10,c-12 CLA or mixed CLA reduced plasma adiponectin levels, whereas t-10,c-12 CLA increased plasma dietary insulin levels. Liver triglycerides correlated directly with blood glucose and plasma insulin and inversely with plasma adiponectin. We conclude that linoleic dietary supplementation with CLA does not affect atherosclerosis of the apoE(-/-) mouse on a high-cholesterol diet. Furthermore, t-10,c-12 CLA causes of adverse changes in adipocyte function and plasma and liver lipid metabolism, which are partially ameliorated by the inclusion of the dietary c-9,t-11 CLA isomer.